近年来,国内创新药研发活跃度持续攀升,国产1类创新药正不断获批上市。据统计显示,截至 2025 年 12 月 15 日,已有超50款国产1类创新药获批上市。如12月12日,中国生物制药发布公告,自主研发的国家1类创新药库莫西利胶囊(商品名:赛坦欣®)已获得中国国家药品监督管理局(NMPA)的上市批准,用于与氟维司群联合治疗既往接受内分泌治疗后出现疾病进展的激素受体(HR)阳性、人表皮生长因子受体2...
Source Link近年来,国内创新药研发活跃度持续攀升,国产1类创新药正不断获批上市。据统计显示,截至 2025 年 12 月 15 日,已有超50款国产1类创新药获批上市。如12月12日,中国生物制药发布公告,自主研发的国家1类创新药库莫西利胶囊(商品名:赛坦欣®)已获得中国国家药品监督管理局(NMPA)的上市批准,用于与氟维司群联合治疗既往接受内分泌治疗后出现疾病进展的激素受体(HR)阳性、人表皮生长因子受体2...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.